Long-term Survival in Patients Undergoing Radical Nephrectomy and Inferior Vena Cava Thrombectomy: Single-Center Experience
|
|
- Stanley Bryan
- 6 years ago
- Views:
Transcription
1 EUROPEAN UROLOGY 57 (2010) available at journal homepage: Kidney Cancer Long-term Survival in Patients Undergoing Radical Nephrectomy and Inferior Vena Cava Thrombectomy: Single-Center Experience Gaetano Ciancio, Murugesan Manoharan, Devendar Katkoori, Rosely De Los Santos, Mark S. Soloway * Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA Article info Article history: Accepted June 9, 2009 Published online ahead of print on June 21, 2009 Keywords: Inferior vena cava Thrombectomy Radical nephrectomy Survival Long term Abstract Background: Renal cell carcinoma (RCC) with a tumor thrombus extension into the inferior vena cava (IVC) demands aggressive surgical management. Objective: To evaluate the long-term survival in patients undergoing radical nephrectomy and IVC thrombectomy. Design, setting, and participants: We performed a retrospective analysis of 87 patients undergoing surgery between 1997 and The patients were grouped according to the extent of tumor thrombus, with level I involving the IVC at the level of the renal vein, level II being infrahepatic IVC, level III being intrahepatic IVC, and level IV being suprahepatic IVC or right atrium. Relevant clinical and pathologic data were analyzed. Measurements: Disease-free survival (DFS) and disease-specific survival (DSS) were studied. Results and limitations: The median follow-up was 22 mo, and 19, 14, 40, and 14 patients had level I, II, III, and IV IVC thrombus, respectively. Among patients with M0 disease, 22 developed metastases. The 5-yr DFS was 64% for all levels and 74%, 69.5%, 59.5%, and 58% for levels I, II, III, and IV, respectively. Of the level I group, 16% of patients died of disease compared to 57% of the level IV group. The 5-yr DSS for all levels was 46% and 71%, 48%, 40%, and 35% for levels I, II, III, and IV, respectively. Patients with level IV thrombus had a significantly lower 5-yr DSS compared to level I ( p = 0.03). However, when analyzed in two groups supradiaphragmatic and infradiaphragmatic there was no significant difference in DSS (P = 0.14). On univariate analysis, metastasis at presentation, non clear-cell histology, lymph node metastases, and higher nuclear grade were statistically significant prognostic factors influencing DSS. Only higher nuclear grade ( p = 0.03), metastasis at presentation ( p < 0.01), and non clear-cell histology ( p = 0.03) were independent prognostic factors on multivariate analysis. Conclusions: Radical nephrectomy and IVC thrombectomy offer reasonable longterm survival. The level of tumor thrombus is not an independent prognostic factor. Distant metastasis at presentation, higher nuclear grade, and non clear-clear cell histology are significant prognostic factors influencing DSS. # 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Department of Urology, University of Miami School of Medicine, P.O. Box , Miami, FL 33101, USA. Tel ; Fax: address: msoloway@med.miami.edu (M.S. Soloway) /$ see back matter # 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 668 EUROPEAN UROLOGY 57 (2010) Introduction Renal cell carcinoma (RCC) accounts for 3.5% of all adult malignant neoplasms [1,2]. It is the most lethal of all the urologic cancers, with a 40% mortality rate, and accounts for 2.3% of cancer-related deaths. RCC has a tendency to invade the renal venous system and form a tumor thrombus that can extend into the inferior vena cava (IVC). Nearly 4 10% of RCC cases have a tumor thrombus involving the IVC, and in 1% of cases, the tumor thrombus extends into the right atrium [3]. Since the first description of nephrectomy with IVC thrombectomy in 1913 by Berg [4], aggressive surgical management has significantly improved the outcome for patients with RCC and associated IVC thrombus. Studies document 45 69% 5-yr survival rates for patients with venous tumor thrombi in the absence of metastases [5]. Identifying the level of tumor thrombus is an important step in disease management, given that the level of tumor thrombus dictates the surgical approach [6]. Whether the level of thrombus independent of pathologic stage has an impact on survival is still a controversial topic. It is known, however, that higher-level tumor thrombi tend to be associated with a higher grade and a more advanced T stage. We analyzed patients undergoing surgery for RCC and tumor thrombus extension into the IVC to evaluate longterm survival. 2. Materials and methods We retrospectively analyzed all of the patients who underwent radical nephrectomy (RN) and IVC thrombectomy at our institution from 1997 to After obtaining Institutional Review Board approval, all relevant study variables were entered into a database and analyzed. We divided the patients into four groups: (1) level I, tumor thrombus involving the IVC at the level of the renal vein; (2) level II, infrahepatic IVC; (3) level III, intrahepatic IVC; and (4) level IV, suprahepatic IVC or right atrium involvement [6,7]. We did not differentiate IVC involvement in terms of tumor infiltration versus tumor thrombus alone, as this information was not uniformly reported. The 1997 World Health Organization (WHO) classification was used to classify the histologic subtype as clear cell or non clear cell. The Fuhrman grading system was used for reporting nuclear grade. The revised 2002 American Joint Committee on Cancer TNM system was used for pathologic staging. The outcome variables studied were disease-free survival (DFS), diseasespecific survival (DSS), and overall survival (OS). The surgical technique has been described in detail in a previous publication [6,8]; however, the extent of surgical dissection is dictated by the extent and level of the tumor thrombus. We use livertransplantation techniques and mobilize the liver off of the IVC to separate the IVC from the posterior abdominal wall. This maneuver provides excellent exposure, and the vascular control is also good. We adopt a totally intra-abdominal approach without cardiopulmonary bypass (CPB) or a veno-venous bypass. In our series, we used CPB in only three patients [6]. The patients were followed postsurgery at 1 mo, and then every 3 mo with history, physical examination, metabolic panel, and liver function tests. A chest x-ray was obtained every 6 mo, and an abdominal computed tomography scan was obtained every year. Statistical analysis was performed using the SPSS v.16 (SPSS, Chicago, IL, USA). A two-sided p value 0.05 was considered statistically significant. For univariate analysis, the Kaplan-Meier method for survival analysis and the log-rank test were used. The Cox proportional hazards regression model was used for multivariate analysis of the prognostic factors. 3. Results In total, 87 patients were included in the study. Nine patients had M1 disease; among those nine patients, six had nonpulmonary metastases. All patients with M1 disease underwent surgery in view of pain and hematuria. The Eastern Cooperative Oncology Group performance status was available for five patients: It was 0 for two patients and 1 for three patients. Table 1 summarizes patient variables for the entire cohort and for various level groups. CPB was used in three patients. In other patients, for whom access to the atrium was required, the procedure was performed by opening the diaphragm transabdominally. A veno-venous bypass was not used in any patient. The perioperative mortality rate was 3.5%, with three perioperative deaths. Although no intraoperative deaths were noted, two of the deaths occurred on the first postoperative day in the level III group, one as a result of cardiac arrhythmia and the other the result of pulmonary failure in a patient with chronic obstructive pulmonary disease. The third death occurred as a result of hepatic failure in a patient with level IV thrombus and Budd-Chiari syndrome. No pulmonary embolisms were noted in any of these patients, and none of these patients had a CPB. The median follow-up was 22 mo (range: 3 99). Of the 78 patients who were free of distant metastases at the time of surgery, 22 patients (28%) developed metastases. The sites where metastases occurred were lung (n = 13), brain (n = 2), bone (n = 2), and liver (n = 1), and, in four patients, metastases occurred at multiple sites. There was one local recurrence in a patient operated with a level IV thrombus: This patient also developed metastases at multiple sites. One-fourth of patients in the level II group developed distant metastases compared to nearly one-third of patients in the level III and level IV groups. Table 2 summarizes the data on metastases in each group and the 5-yr DFS calculated for these 78 patients. The difference in DFS between the groups was not statistically significant ( p = 0.7). In the entire cohort, 32 disease-specific deaths were observed. The median time to death was 17 mo (range: 3 42). Of patients with level I thrombus, 16% died, in contrast to 57% patients with level IV thrombus (Table 2). The 5-yr OS and DSS are summarized in Table 2. Patients with level IV thrombus had a significantly lower 5-yr DSS compared to patients with level I thrombus ( p = 0.03). There was no significant difference in DSS among levels II, III, and IV (Fig. 1). Further analysis compared levels I III as one group (below the diaphragm) and level IV (above the diaphragm) as another group, similar to the TNM classification; there was no statistically significant difference in DSS between the groups ( p = 0.14; Fig. 2). Patients with metastases at presentation experienced high mortality. One patient died perioperatively, one patient died as a result of a pelvic fracture 3 mo after surgery, and seven patients died of disease. The median time to death in these patients was 8 mo (range: 0 27; mean: 10.5 mo).
3 EUROPEAN UROLOGY 57 (2010) Table 1 Summary of study variables Study variable All levels Level I Level II Level III Level IV p value * Patients, no. (%) (22) 14 (16) 40 (46) 14 (16) Age, yr y Gender Male 47 (54) 6 (31.5) 8 (57) 27 (67.5) 6 (43) 0.06 Female 40 (46) 13 (68.5) 6 (43) 13 (32.5) 8 (57) Side Right 60 (69) 6 (31.5) 11 (78.5) 34 (85) 9 (64) Left 27 (31) 13 (68.5) 3 (21.5) 6 (15) 5 (36) Tumor size (cm SD) y T stage 3b 69 (80) 17 (90) 13 (93) 39 (97.5) 0 3c 11 (12) (78.5) 4 7 (8) 2 (10) 1 (7) 1 (2.5) 3 (21.5) N+ patients, no. (%) 18 (20.5) 2 (10.5) 2 (14) 11 (27.5) 3 (21.5) 0.45 M+ patients, no. (%) 9 (10.5) 0 2 (14) 4 (10) 3 (21.5) 0.25 Histologic type Clear cell 62 (71) 15 (79) 9 (64) 28 (70) 10 (71.5) 0.8 Non clear cell 25 (29) 4 (21) 5 (36) 12 (30) 4 (28.5) Nuclear grade II 14 (16) 3 (16) 3 (21.5) 7 (17.5) 1 (7) 0.1 III 40 (46) 7 (37) 8 (57) 16 (40) 9 (65) IV 24 (28) 5 (26) 0 17 (42.5) 2 (14) Missing 9 (10) 4 (21) 3 (21.5) 0 2 (14) SD = standard deviation; ANOVA = analysis of variance. * All p values are two sided. y ANOVA; others are Pearson x 2 test. Table 2 Survival analysis: 5-year disease-free, disease-specific, and overall survival All levels Level I Level II Level III Level IV Metastases *, no. (%) 22:78 3 (16) 3 (25) 12 (33) 4 (36) 5-yr DFS (SE) * 64 (6.5) 74 (14) 69 (15) 59 (10) 58 (17) Death, no. (%) 32 3 (16) 5 (36) 18 (45) 8 (57) 5-yr OS (SE) 39 (6) 63 (13) 41 (17) 35 (10) 30 (15) 5-yr DSS (SE) 46 (7) 71 (14) 48 (16) 40 (10) 35 (14) 5-yr DSS (SE) 49 (8) Below the diaphragm 35 (14) Above the diaphragm DFS = disease-free survival; SE = standard error; OS = overall survival; DSS = disease-specific survival. * Calculated for patients with M0 status at the time of surgery. On univariate analysis, metastasis at presentation ( p = 0.01), non clear-cell histology ( p = 0.02), lymph node metastases ( p = 0.02), and higher nuclear grade ( p = 0.02) were statistically significant prognostic factors influencing DSS. Independent prognostic factors on multivariate analysis were higher nuclear grade ( p = 0.03), metastasis at presentation ( p < 0.01), and non clear-cell histology ( p = 0.03) (Table 3). Level of thrombus itself was not an independent prognostic factor. 4. Discussion Aggressive surgical treatment is indicated in all patients with RCC and IVC thrombus, as nephrectomy alone is associated with a dismal prognosis [9]. RN with IVC thrombectomy is one of the most challenging surgeries; however, a multitude of developments have made this procedure reasonably safe. Advances in surgical technique, intraoperative monitoring, and judicious use of CPB all contribute to a safer perioperative outcome. This procedure is associated with a perioperative mortality of 3 16% [9 12]. Long-term survival, however, is still low. A 5-yr survival rate from 32% to 64% [7,12,13] has been reported. In our analysis, the 5-yr DSS was 46% for the entire cohort and 54.5% for pn0 M0 disease. Blute et al reported a 59% survival rate for pn0 M0 disease and 5.8% for N1/N2 M1 disease [10]. In the current TNM staging, a tumor thrombus below the diaphragm is staged as T3b; above the diaphragm, it is staged ast3c. This determination is based on the assumption that a higher level of tumor thrombus is associated with a worse prognosis. Although some studies reported lower survival in patients with a more cephalad tumor thrombus, other studies did not report such differences. A large retrospective analysis from 13 European institutions reported a median survival of 52 mo for renal vein thrombus, 26 mo for subdiaphragmatic IVC thrombus, and 18 mo for supradiaphragmatic IVC thrombus. They concluded that IVC invasion at any level significantly and
4 670 EUROPEAN UROLOGY 57 (2010) Fig. 1 Kaplen-Meier plot showing disease-specific survival for different levels of inferior vena cava thrombus. Fig. 2 Kaplan-Meier plot for disease-specific survival in inferior vena cava thrombi in relation to diaphragm. independently decreased the rate of survival; however, the level of tumor thrombus did not significantly alter the OS [11]. In their review of 18 patients with level IV thrombus, Glazer and Novick did not find any significant difference in survival compared to other levels [13]. In a study of 153 patients, Moinzadeh and Libertino reported no significant difference in 5-yr cancer-specific survival (CSS) for all levels of IVC tumor thrombus [14]. In our study, patients with level IV IVC thrombus had a 36% 5-yr survival, which was significantly less than the DSS for patients with level I IVC thrombus. However, there was no statistically significant difference in survival among other levels; also, when grouped in reference to the level of the diaphragm, there was no significant difference in DSS. Kim et al reported similar results for level IV thrombus [15]. IVC thrombus is often associated with metastases at presentation. Most of the series reported in the literature have as many as 30% of patients with M1 disease. IVC thrombectomy is advocated even in the presence of metastases, as it may relieve the symptoms and potentially result in a better quality of life (QoL). A modest benefit has been reported in patients undergoing cytoreductive nephrectomy before giving immunotherapy [16]. A review by Kirkali and Van Poppel concluded that IVC thrombectomy can provide better QoL and may prolong survival even in a metastatic setting [17]. In a report from the Mayo Clinic, the 5-yr CSS was 15% for pn0 M1 disease and 6% for p N1/N2 M1 disease [10]. Staehler and Brkovic reported a median survival of 13 mo and a 26% 2-yr survival in patients with M1 disease [18]. In a series by Lambert et al, patients with metastatic disease did not experience any added morbidity or mortality compared to patients without metastatic disease [19]. In our analysis, 10% of patients had M1 disease, which is lower than in other series, and all of these patients died. The median time to death was 8 mo, with the longest survival at 27 mo. The prognostic significance of the level of tumor thrombus has been controversial. Some studies have reported that the level of tumor thrombus is an independent prognostic factor for survival [20,21]; others did not [13,15,19,22 24]. The presence of IVC invasion, not the level of tumor thrombus, was reported as an independent prognostic factor in some studies [25,26]. Wagner et al reported IVC invasion as an independent prognostic factor ( p = 0.008) [11]. In a review by Kirkali and Van Poppel, the recurrence rates were high, with RCC having vein invasion, and they suggested that this group may benefit from adjuvant therapy [17]. The presence of perinephric fat invasion in a patient with tumor thrombus was identified as a prognostic factor in one study [27]. In our analysis, we found that although a level IV thrombus was a significant predictor of survival on univariate analysis, it was not an independent prognostic factor on multivariate analysis. Metastases at presentation, higher nuclear grade, and non clear-cell histology were found to be independent prognostic factors. These findings emphasize that the primary histologic factors are the more important predictors of prognosis. Table 3 Results of multivariate analysis Variable Univariate Multivariate HR CI p value M1 disease Non clear-cell histology LN Nuclear grade IV HR = hazard ratio; CI = confidence interval; LN+ = lymph node positive.
5 EUROPEAN UROLOGY 57 (2010) Our study had several limitations: It is a retrospective study, the study population is small, and it is a singleinstitution experience. Our study did not attempt to differentiate tumor thrombus infiltration from thrombus alone, as this information was not always available. Our study has a relatively higher number of non clear-cell tumors compared to literature. The prognostic significance of perinephric fat invasion could not be assessed because of inconsistent pathologic data for this variable. Also, the number of patients with M1 disease is lower than other series. 5. Conclusions RN with IVC thrombectomy offers reasonable long-term survival. Although the survival decreased with higher levels of tumor thrombus, the level of tumor thrombus itself is not an independent prognostic factor influencing survival. Distant metastasis at presentation, higher nuclear grade, and non clear-clear cell histology are significant prognostic factors influencing DSS. Author contributions: Mark S. Soloway had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Ciancio, Soloway, Manoharan, Katkoori Acquisition of data: Katkoori, De Los Santos Analysis and interpretation of data: Katkoori, Manoharan, De Los Santos Drafting of the manuscript: Ciancio, Manoharan, Katkoori Critical revision of the manuscript for important intellectual content: Ciancio, Soloway, Manoharan, Katkoori. Statistical analysis: Katkoori, Manoharan, De Los Santos. Obtaining funding: None. Administrative, technical or material support: Ciancio, Soloway, Manoharan. Supervision: Ciancio, Soloway, Manoharan. Other (specify): None. Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None. Funding/Support and role of the sponsor: None. References [1] Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin 2008;58: [2] Wotkowicz C, Wszolek MF, Libertino JA. Resection of renal tumors invading the vena cava. Urol Clin North Am 2008;35: [3] Marshall FF, Dietrick DD, Baumgartner WA, Reitz BA. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol 1988;139: [4] Berg AA. Malignant hypernephroma of the kidney, its clinical course and diagnosis, with a description of the author s method of radical operative cure. Surg Gynecol Obstet 1913;17: [5] Campbell SC, Novick AC, Bukowski RM. Renal tumors 8th ed. In: Walsh PC, Retik AB, Vaughan Jr ED, eds. Campbell s Urology, Vol. 4. Philadelphia, PA: Saunders; p [6] Ciancio G, Livingstone AS, Soloway M. Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: the University of Miami experience in using liver transplantation techniques. Eur Urol 2007;51:988 95, discussion [7] Neves RJ, Zincke H. Surgical treatment of renal cancer with vena cava extension. Br J Urol 1987;59: [8] Ciancio G, Vaidya A, Savoie M, Soloway M. Management of renal cell carcinoma with level III thrombus in the inferior vena cava. J Urol 2002;168: [9] Sosa RE, Muecke EC, Vaughan Jr ED, McCarron Jr JP. Renal cell carcinoma extending into the inferior vena cava: the prognostic significance of the level of vena caval involvement. J Urol 1984;132: [10] Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004;94: [11] Wagner B, Patard J-J, Méjean A, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol 2009;55: [12] Skinner DG, Pritchett TR, Lieskovsky G, Boyd SD, Stiles QR. Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival. Ann Surg 1989;210:387 92, discussion [13] Glazer AA, Novick AC. Long-term followup after surgical treatment for renal cell carcinoma extending into the right atrium. J Urol 1996;155: [14] Moinzadeh A, Libertino JA. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same? J Urol 2004;171: [15] Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol 2004;171: [16] Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171: [17] Kirkali Z, Van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol 2007;52: [18] Staehler G, Brkovic D. The role of radical surgery for renal cell carcinoma with extension into the vena cava. J Urol 2000;163: [19] Lambert EH, Pierorazio PM, Shabsigh A, Olsson CA, Benson MC, McKiernan JM. Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Urology 2007;69: [20] Haferkamp A, Bastian PJ, Jakobi H, et al. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective longterm followup. J Urol 2007;177: [21] Quek ML, Stein JP, Skinner DG. Surgical approaches to venous tumor thrombus. Semin Urol Oncol 2001;19: [22] Tongaonkar HB, Dandekar NP, Dalal AV, Kulkarni JN, Kamat MR. Renal cell carcinoma extending to the renal vein and inferior vena cava: results of surgical treatment and prognostic factors. J Surg Oncol 1995;59: [23] Sweeney P, Wood CG, Pisters LL, et al. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 2003;21:
6 672 EUROPEAN UROLOGY 57 (2010) [24] Tanaka M, Fujimoto K, Okajima E, Tanaka N, Yoshida K, Hirao Y. Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol 2008;15: [25] Hatcher PA, Anderson EE, Paulson DF, Carson CC, Robertson JE. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991;145:20 3, discussion [26] Ljungberg B, Stenling R, Osterdahl B, Farrelly E, Aberg T, Roos G. Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. J Urol 1995;154: [27] Leibovich BC, Cheville JC, Lohse CM, et al. Cancer specific survival for patients with pt3 renal cell carcinoma can the 2002 primary tumor classification be improved? J Urol 2005;173:716 9.
Correspondence to: Jagdeesh Kulkarni,
Original Article Surgical management of renal cell carcinoma with inferior vena caval thrombus: A teaching hospital experience Kulkarni Jagdeesh N, Acharya Purushothama U, Rizvi S Jamal, Somaya Anand C*
More informationPrognostic Impact of the 2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma with Venous Extension
EUROPEAN UROLOGY 59 (2011) 120 127 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Prognostic Impact of the 2009 UICC/AJCC TNM Staging System for Renal Cell Carcinoma
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationPrognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma
european urology 55 (2009) 452 460 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal
More informationImpact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific Survival in Patients with Renal Cell Carcinoma
EUROPEAN UROLOGY 60 (2011) 358 365 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Impact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific
More informationImpact of lymphadenectomy in management of renal cell carcinoma
Journal of the Egyptian National Cancer Institute (2012) 24, 57 61 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com ORIGINAL ARTICLE Impact of
More informationIVC THROMBECTOMY: OPEN
IVC THROMBECTOMY: OPEN Gennady Bratslavsky, M.D. Professor and Chairman Department of Urology SUNY Upstate Medical University Syracuse, NY Disclosures None I am not an ideal candidate to argue for open
More informationThe Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus
Original Article SURGERY, COMPLICATIONS AND OUTCOME OF RCC WITH THROMBUS BLUTE et al. The Mayo clinic experience with renal carcinoma and venous tumour thrombus is presented in this section. The authors
More informationClinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience
Chen et al. World Journal of Surgical Oncology (2015) 13:14 DOI 10.1186/s12957-015-0448-2 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Clinical and oncological outcomes in Chinese patients with
More informationWe are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%
We are IntechOpen, the first native scientific publisher of Open Access books 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our authors are among the 151 Countries
More informationeuropean urology 51 (2007)
european urology 51 (2007) 988 995 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Surgical Management of Renal Cell Carcinoma with Tumor Thrombus in the Renal
More informationPrognostic factor for Korean patients with renal cell carcinoma and venous tumor thrombus extension: application of the new 2009 TNM staging system
ORIGINAL Article Vol. 39 (3): 353-363, May - June, 2013 doi: 10.1590/S1677-5538.IBJU.2013.03.08 Prognostic factor for Korean patients with renal cell carcinoma and venous tumor thrombus extension: application
More informationDebate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.
Debate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.. Eighth European International Kidney Cancer Symposium Budapest 03-04 May 2013 The role of LND In organ confined
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationRenal and adrenal tumors might involve the inferior vena cava
Surgery for Acquired Cardiovascular Disease Cavoatrial tumor thrombus: Single-stage surgical approach with profound hypothermia and circulatory arrest, including a review of the literature Bruno Chiappini,
More informationRenal cell carcinoma (RCC), one of the most lethal urologic cancers,
REVIEW Locally advanced renal cell carcinoma Mohammed Al Otaibi, MD; Simon Tanguay, MD Abstract Despite the observed stage migration and earlier detection of renal masses, patients still present with locally
More informationRenal cell carcinoma with extension of tumor thrombus into the vena cava: Surgical strategy and prognosis
Renal cell carcinoma with extension of tumor thrombus into the vena cava: Surgical strategy and prognosis Yoshihiko Tsuji, MD, a Akinobu Goto, MD, b Isao Hara, MD, b Keiji Ataka, MD, a Chojiro Yamashita,
More informationIs There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
EUROPEAN UROLOGY 59 (2011) 258 263 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented
More informationSurgical Management of Renal Cell Carcinoma (RCC) with Vena Cava Tumour Thrombus
european urology supplements 5 (2006) 610 618 available at www.sciencedirect.com journal homepage: www.europeanurology.com Surgical Management of Renal Cell Carcinoma (RCC) with Vena Cava Tumour Thrombus
More informationHirono et al. BMC Cancer 2013, 13:447
Hirono et al. BMC Cancer 2013, 13:447 RESEARCH ARTICLE Open Access Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus
More informationFinancial and Other Disclosures
Financial and Other Disclosures Off-label use of drugs, devices, or other agents: None Data from IRB-approved human research is not presented I have the following financial interests or relationships to
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationHatakeyama et al. BMC Urology 2013, 13:47
Hatakeyama et al. BMC Urology 2013, 13:47 RESEARCH ARTICLE Open Access Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior
More informationEUROPEAN UROLOGY 60 (2011)
EUROPEAN UROLOGY 60 (2011) 458 464 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priorty Kidney Cancer Editorial by Christian G. Stief on pp. 465 466 of this issue
More informationPrognostic factors in localized renal cell cancer
Original Article PROGNOSTIC FACTORS IN LOCALIZED RENAL CELL CANCER KNIGHT and STADLER Prognostic factors in localized renal cell cancer David A. Knight and Walter M. Stadler Section of Hematology/Oncology,
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationPrognostic Factors and Staging Systems for Renal Cell Carcinoma
european urology supplements 6 (2007) 623 629 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors and Staging Systems for Renal Cell Carcinoma Vincenzo Ficarra
More informationThe new TNM staging for renal cell carcinoma: what and why the urologists want to know.
The new TNM staging for renal cell carcinoma: what and why the urologists want to know. Poster No.: C-1132 Congress: ECR 2011 Type: Educational Exhibit Authors: Y. Y. Lim, A. Hattab, A. Bradley ; Manchester/UK,
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationOverall Survival and Development of Stage IV Chronic Kidney Disease in Patients Undergoing Partial and Radical Nephrectomy for Benign Renal Tumors
EUROPEAN UROLOGY 64 (2013) 600 606 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Alexander Kutikov, Marc C. Smaldone and Robert
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More informationRadical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients
Original Article : oncologic outcome in 271 Chinese patients Zhi-Ling Zhang, Pei Dong, Yong-Hong Li, Zhuo-Wei Liu, Kai Yao, Hui Han, Zi-Ke Qin and Fang-Jian Zhou Abstract Few large scale studies have reported
More informationSurgery for retrohepatic caval thrombus in patients with advanced renal cell carcinoma: a case series
Polańska-Płachta et al. World Journal of Surgical Oncology (2016) 14:11 DOI 10.1186/s12957-015-0765-5 RESEARCH Open Access Surgery for retrohepatic caval thrombus in patients with advanced renal cell carcinoma:
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationeuropean urology 50 (2006)
european urology 50 (2006) 302 310 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Surgical Care, Morbidity, Mortality and Follow-up after Nephrectomy for Renal
More informationGuidelines on Renal Cell
Guidelines on Renal Cell Carcinoma (Text update March 2009) B. Ljungberg (Chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction Renal cell carcinoma
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (2012) 1156 1161 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Alvin C. Goh and Inderbir S. Gill on pp. 1162
More informationPartial Nephrectomy Techniques for Renal Preservation: Historical and Modern Approaches
Partial Nephrectomy Techniques for Renal Preservation: Historical and Modern Approaches Cary N Robertson MD FACS Associate Professor Division of Urology Associate Director Urologic Oncology Duke Cancer
More informationPROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS
More informationIndications For Partial
Indications For Partial Nephrectomy Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship in Urology Department of Urology The University of Texas
More informationHand-Assisted Laparoscopic Radical Nephrectomy in the Treatment of a Renal Cell Carcinoma with a Level II Vena Cava Thrombus
Surgical Technique Laparoscopic Excision of an RCC with Level II thrombus International Braz J Urol Vol. 36 (3): 327-331, May - June, 2010 doi: 10.1590/S1677-55382010000300009 Hand-Assisted Laparoscopic
More informationSurgical Management of Renal Cancer. David Nicol Consultant Urologist
Surgical Management of Renal Cancer David Nicol Consultant Urologist Roles of Surgery 1. Curative intervention localised disease 2. Symptomatic control advanced disease 3. Augmentation of efficacy of systemic
More informationCase Report Formation of a Tunnel under the Major Hepatic Vein Mouths during Removal of IVC Tumor Thrombus
Case Reports in Urology Volume 2013, Article ID 129632, 4 pages http://dx.doi.org/10.1155/2013/129632 Case Report Formation of a Tunnel under the Major Hepatic Vein Mouths during Removal of IVC Tumor Thrombus
More informationSurgically Discovered Xanthogranulomatous Pyelonephritis Invading Inferior Vena Cava with Coexisting Renal Cell Carcinoma
Case Study TheScientificWorldJOURNAL (2009) 9, 5 9 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.6 Surgically Discovered Xanthogranulomatous Pyelonephritis Invading Inferior Vena Cava with Coexisting
More informationSurgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology
Surgeons Perspective: LN as a Draining Pattern Jose A. Karam, MD, FACS Associate Professor Department of Urology Disclosures EMD Serono, Pfizer, Novartis: Advisory board/consultant Disclosures I perform
More informationRenal Mass Biopsy: Needed Now More than Ever
Renal Mass Biopsy: Needed Now More than Ever Stuart G. Silverman, MD, FACR Professor of Radiology Harvard Medical School Director, Abdominal Imaging and Intervention Brigham and Women s Hospital Boston,
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationRenal Carcinoma With Supradiaphragmatic Tumor Thrombus: Avoiding Sternotomy and Cardiopulmonary Bypass
Renal Carcinoma With Supradiaphragmatic Tumor Thrombus: Avoiding Sternotomy and Cardiopulmonary Bypass Gaetano Ciancio, MD, Samir P. Shirodkar, MD, Mark S. Soloway, MD, Alan S. Livingstone, MD, Michael
More informationThe Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma
european urology supplements 7 (2008) 63 70 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationRenal and Adrenal Tumors with Cardiac Invasion: Immediate Surgical Results in 14 Patients
Renal and Adrenal Tumors with Cardiac Invasion: Immediate Surgical Results in 14 Patients Rafael Fagionato Locali, Priscila Katsumi Matsuoka, Tiago Cherbo, Edmo Atique Gabriel, Enio Buffolo Universidade
More informationUrinary Collecting System Invasion is an Independent Prognostic. Factor in Organ Confined Renal Cell Carcinomas.
Author manuscript, published in "Journal of Urology The 2009;182(3):854-9" DOI : 10.1016/j.juro.2009.05.017 Urinary Collecting System Invasion is an Independent Prognostic Factor in Organ Confined Renal
More informationClinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationValidation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance Index
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.8.524 Urological Oncology Validation of the 2009 TNM Classification for Renal Cell Carcinoma: Comparison with the 2002 TNM Classification by Concordance
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationManagement of Locally Reccurent Renal Cell Carcinoma. Jose A. Karam, MD, FACS Assistant Professor Department of Urology
Management of Locally Reccurent Renal Cell Carcinoma Jose A. Karam, MD, FACS Assistant Professor Department of Urology DefiniAons Defini&ve treatment Aiming for cure Abla&on therapy Radiofrequency abla&on
More informationPartial Nephrectomy Is Associated with Improved Overall Survival Compared to Radical Nephrectomy in Patients with Unanticipated Benign Renal Tumours
EUROPEAN UROLOGY 58 (2010) 293 298 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Partial Nephrectomy Is Associated with Improved Overall Survival Compared to
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1428 1437 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase
More informationInitial Series of Robotic Radical Nephrectomy with Vena Caval Tumor Thrombectomy
EUROPEAN UROLOGY 59 (2011) 652 656 available at www.sciencedirect.com journal homepage: www.europeanurology.com Case Series of the Month Initial Series of Robotic Radical Nephrectomy with Vena Caval Tumor
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationI mportant prognostic factors in renal cell carcinoma (RCC)
39 ORIGINAL ARTICLE Prognostic relevance of extensive necrosis in renal cell carcinoma V Foria, T Surendra, D N Poller... See end of article for authors affiliations... Correspondence to: Dr D N Poller,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationSolitary Contralateral Adrenal Metastases after Nephrectomy for Renal Cell Carcinoma
Original Report ISSN 1537-744X; DOI 10.1100/tsw.2004.39 Solitary Contralateral Adrenal after Nephrectomy for Renal Cell Carcinoma Nikolaos Antoniou, M.D. and Demetrios Karanastasis, M.D. General Hospital
More informationIs renal cryoablation becoming an effective alternative to partial nephrectomy?
Is renal cryoablation becoming an effective alternative to partial nephrectomy? J GARNON 1, G TSOUMAKIDOU 1, H LANG 2, A GANGI 1 1 department of interventional radiology 2 department of urology University
More informationNephron-Sparing Surgery versus Radical Nephrectomy in the Treatment of Intracapsular Renal Cell Carcinoma up to 7 cm
european urology 53 (2008) 803 809 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Nephron-Sparing Surgery versus Radical Nephrectomy in the Treatment of Intracapsular
More informationPatient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
DOI:10.22034/APJCP.2018.19.4.891 RESEARCH ARTICLE Editorial Process: Submission:01/04/2017 Acceptance:09/11/2017 Patient Reported Weight Loss Predicts Recurrence Rate in Renal Cell Cancer Cases after Nephrectomy
More informationComparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population
DOI 10.1007/s10147-015-0812-9 ORIGINAL ARTICLE Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population Yasunobu
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationDevelopment of a surgical safety checklist for the performance of radical nephrectomy and tumor thrombectomy
Joshi et al. Patient Safety in Surgery 2012, 6:27 REVIEW Open Access Development of a surgical safety checklist for the performance of radical nephrectomy and tumor thrombectomy Shivam Joshi 1, Michael
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationEUROPEAN UROLOGY 64 (2013)
EUROPEAN UROLOGY 64 (213) 37 313 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic
More informationMetastatic Potential in Renal Cell Carcinomas =7 cm: Swedish Kidney Cancer Quality Register Data
EUROPEAN UROLOGY 60 (2011) 975 982 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Eric C. Umbreit and R. Houston Thompson on pp.
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationRadical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study
AJCP /ORIGINAL ARTICLE Radical Nephrectomy for Renal Cell Carcinoma Its Contemporary Role Related to Histologic Type, Tumor Size, and Nodal Status: A Retrospective Study Kamran M. Mirza, MD, PhD, Jerome
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationVincenzo Ficarra. Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine
Best Papers on Kidney Cancer Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine Uro-oncological oncological topics Renal Tumor biopsy Positive Surgical Margins after
More informationValidation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationCarcinoma renale (I): Posters Review. Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano
Carcinoma renale (I): Posters Review Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano Agenda: Best Posters in Localized RCC Surgery: CN (#
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma The Harvard community has made this article
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationClinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma Associated with End-stage Renal Disease
Jpn J Clin Oncol 2014;44(11)1096 1100 doi:10.1093/jjco/hyu117 Advance Access Publication 19 August 2014 Clinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationJohn Fitzpatrick Memorial Lecture. John Fitzpatrick Memorial lecture
John Fitzpatrick Memorial Lecture John Fitzpatrick Memorial Lecture John M Fitzpatrick, 1948 2014 Head of Research at the Irish Cancer Society Professor of Surgery and Consultant Urologist at the Mater
More information